脳科学辞典

「内因性オピオイド」の版間の差分

ページ

内因性オピオイド (ソースを閲覧)

2025年8月15日 (金) 17:26時点における版

860 バイト除去 、 2025年8月15日 (金)
細
編集の要約なし
細編集の要約なし
49行目: 49行目:
| [[α-エンドルフィン]] || YGGFMTSEKSQTPLVT || μ-オピオイド受容体、他のオピオイド受容体への親和性は不明 || <ref name="Endogenous opioid families - 2012 review" />
| [[α-エンドルフィン]] || YGGFMTSEKSQTPLVT || μ-オピオイド受容体、他のオピオイド受容体への親和性は不明 || <ref name="Endogenous opioid families - 2012 review" />
|-
|-
| [[β-エンドルフィン]]|| YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE || μ-オピオイド受容体<sup>†‡</sup>、δ-オピオイド受容体<sup>†</sup> || <ref name="Endogenous opioid families - 2012 review" /><ref name="IUPHAR Opioid receptors - Introduction" /><ref name="IUPHAR - δ-opioid receptor">{{cite web | title=δ receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=15 May 2017 | quote = Principal endogenous agonists (Human) [are]<br />β-endorphin (POMC, P01189), [Leu]enkephalin (PENK, P01210), [Met]enkephalin (PENK, P01210)}}</ref><ref name="IUPHAR - μ-opioid receptor">{{cite web | title=μ receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=15 March 2017 | quote = Comments: β-Endorphin is the highest potency endogenous ligand&nbsp;...<br />Morphine occurs endogenously ([[#Poeaknapo|Poeaknapo et. al. 2004]])&nbsp;...<br />Principal endogenous agonists (Human) [are]<br />β-endorphin (POMC, P01189), [Met]enkephalin (PENK, P01210), [Leu]enkephalin (PENK, P01210)}}</ref><ref><pubmed>15383669</pubmed></ref>
| [[β-エンドルフィン]]|| YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE || μ-オピオイド受容体<sup>†‡</sup>、δ-オピオイド受容体<sup>†</sup> || <ref name="Endogenous opioid families - 2012 review" /><ref name="IUPHAR Opioid receptors - Introduction" /><ref name="IUPHAR - δ-opioid receptor">{{cite web | title=δ receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=15 May 2017 }}</ref><ref name="IUPHAR - μ-opioid receptor">{{cite web | title=μ receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=15 March 2017}}</ref><ref><pubmed>15383669</pubmed></ref>
|-
|-
| [[γ-エンドルフィン]] || YGGFMTSEKSQTPLVTL || μ-オピオイド受容体、他のオピオイド受容体への親和性は不明 || <ref name="Endogenous opioid families - 2012 review" />
| [[γ-エンドルフィン]] || YGGFMTSEKSQTPLVTL || μ-オピオイド受容体、他のオピオイド受容体への親和性は不明 || <ref name="Endogenous opioid families - 2012 review" />
61行目: 61行目:
| [[ダイノルフィンB]] || YGGFLRRQFKVVT || κ-オピオイド受容体 || <ref name="Endogenous opioid families - 2012 review" /><ref name="IUPHAR Opioid receptors - Introduction" />
| [[ダイノルフィンB]] || YGGFLRRQFKVVT || κ-オピオイド受容体 || <ref name="Endogenous opioid families - 2012 review" /><ref name="IUPHAR Opioid receptors - Introduction" />
|-
|-
| [[ビッグダイノルフィン]] || YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT || κ-オピオイド受容体<sup>†‡</sup> || <ref name="IUPHAR - κ-opioid receptor">{{cite web | title=κ receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=21 February 2017 | quote = Comments: Dynorphin A and big dynorphin are the highest potency endogenous ligands&nbsp;...<br />Principal endogenous agonists (Human) [are]<br />big dynorphin (PDYN, P01213), dynorphin A (PDYN, P01213)}}</ref><ref name="IUPHAR - Big dynorphin - Biological activity">{{cite web | title=Big dynorphin: Biological activity|url=http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=3669 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 20 October 2017 | quote = Principal endogenous agonists at κ receptor}}.</ref><ref name="IUPHAR - Big dynorphin - Structure">{{cite web | title=Big dynorphin: Structure&nbsp;– Peptide Sequence | url=http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=3669 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 20 October 2017 | quote = Peptide sequence<br />YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT}}</ref>
| [[ビッグダイノルフィン]] || YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT || κ-オピオイド受容体<sup>†‡</sup> || <ref name="IUPHAR - κ-opioid receptor">{{cite web | title=κ receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=21 February 2017}}</ref><ref name="IUPHAR - Big dynorphin - Biological activity">{{cite web | title=Big dynorphin: Biological activity|url=http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=3669 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 20 October 2017}}.</ref><ref name="IUPHAR - Big dynorphin - Structure">{{cite web | title=Big dynorphin: Structure&nbsp;– Peptide Sequence | url=http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=3669 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 20 October 2017}}</ref>
|-
|-
| [[ロイモルフィン]] || YGGFLRRQFKVVTRSQEDPNAYYEELFDV || κ-オピオイド受容体 || <ref name="Dynorphins 2009 review"><pubmed>19481570</pubmed></ref><ref name="PubChem - Leumorphin"><pubmed>6149506</pubmed></ref><ref name="Leumorphin primary 2"><pubmed>7908725</pubmed></ref>
| [[ロイモルフィン]] || YGGFLRRQFKVVTRSQEDPNAYYEELFDV || κ-オピオイド受容体 || <ref name="Dynorphins 2009 review"><pubmed>19481570</pubmed></ref><ref name="PubChem - Leumorphin"><pubmed>6149506</pubmed></ref><ref name="Leumorphin primary 2"><pubmed>7908725</pubmed></ref>
71行目: 71行目:
! scope="col" colspan="4" | [[ノシセプチン]]
! scope="col" colspan="4" | [[ノシセプチン]]
|-
|-
| [[ノシセプチン]] || FGGFTGARKSARKLANQ || [[ノシセプチン受容体]]<sup>†‡</sup> || <ref name="Endogenous opioid families - 2012 review" /><ref name="IUPHAR Opioid receptors - Introduction" /><ref name="IUPHAR - nociceptin receptor">{{cite web | title=NOP receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=18 August 2017 | quote = Natural/Endogenous Ligands<br />nociceptin/orphanin FQ}}</ref>
| [[ノシセプチン]] || FGGFTGARKSARKLANQ || [[ノシセプチン受容体]]<sup>†‡</sup> || <ref name="Endogenous opioid families - 2012 review" /><ref name="IUPHAR Opioid receptors - Introduction" /><ref name="IUPHAR - nociceptin receptor">{{cite web | title=NOP receptor|url=http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 | work= IUPHAR/BPS Guide to PHARMACOLOGY | publisher=International Union of Basic and Clinical Pharmacology | access-date= 28 December 2017 | date=18 August 2017}}</ref>
|-
|-
! scope="col" colspan="4" | [[エンドモルフィン]]
! scope="col" colspan="4" | [[エンドモルフィン]]
「https://bsd.neuroinf.jp/wiki/特別:携帯機器差分/51349」から取得